RxDoctor Payments DataLook up a doctor →

Bryan Faller, MD

Hematology & Oncology · Saint Louis, MONPI 1790870178

Payments from drug & device makers

$847,668in general payments, 2019–2025

Across 454 payments — averaging $1867.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$720K
  • Pfizer$37K
  • Bristol Myers Squibb$27K
  • Astrazeneca UK Limited$20K
  • Genentech, Inc.$17K
  • F. Hoffmann-la Roche AG$12K
  • plus $16K from 54 others
$478in research payments, 2019–2025

Across 1 payment — averaging $478.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$478

What the payments were for

  • Food & beverage$6,25098%
  • Education$1132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.39$719,938
Pfizer72$37,317
Bristol Myers Squibb35$26,550
Astrazeneca UK Limited1$19,750
Genentech, Inc.9$16,556
F. Hoffmann-la Roche AG6$11,689
AstraZeneca8$5,803
Exelixis Inc.11$4,787
Novartis23$440
Johnson & Johnson(2 entities)24$417
Genentech USA, Inc.18$378
AbbVie12$277
Merck14$241
Regeneron Healthcare Solutions, Inc.8$207
Incyte Corporation12$205
Boehringer Ingelheim9$179
Pharmacyclics LLC, An Abbvie Company7$165
Gilead(2 entities)7$146
Takeda Pharmaceuticals U.S.A., Inc.7$139
Bayer9$135
Lilly USA, LLC7$135
Sanofi7$131
Stemline Therapeutics Inc.7$130
EMD Serono, Inc.6$128
GSK6$126
Amgen5$108
Beigene USA, Inc.5$97
Ipsen Biopharmaceuticals, Inc4$95
Tersera Therapeutics LLC5$93
Karyopharm Therapeutics Inc.4$83
Astellas Pharma US Inc4$71
Daiichi Sankyo Inc.3$70
Rigel Pharmaceuticals, Inc.4$62
Blueprint Medicines Corporation3$55
Jazz Pharmaceuticals Inc.2$54
ADC Therapeutics America, Inc.2$50
AVEO Pharmaceuticals, Inc.3$49
Taiho Oncology, Inc.3$49
Beone Medicines USA, Inc.2$46
Springworks Therapeutics, Inc.2$46
Seagen Inc.3$46
Puma Biotechnology, Inc.3$43
Sobi, Inc2$42
Pharmaessentia USA Corporation2$41
Eisai Inc.2$38
CTI Biopharma Corp.2$35
Morphosys, US Inc.2$34
Coherus Oncology, Inc.2$31
Agios Pharmaceuticals, Inc.2$29
Sirtex Medical Inc2$28
Telix Pharmaceuticals1$28
Lexicon Pharmaceuticals, Inc.2$27
Array Biopharma Inc2$26
Acrotech Biopharma Inc.2$26
Caris MPI, Inc.1$26
Mirati Therapeutics, Inc.1$25
Deciphera Pharmaceuticals Inc.1$24
Aurobindo Pharma USA, Inc.1$22
Dendreon Pharmaceuticals LLC1$21
Servier Pharmaceuticals LLC1$21

How this compares

$847,668 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$103,358
Medicare patients
277
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$694,497
ImbruvicaIbrutinib24$407,183
JakafiRuxolitinib Phosphate12$211,197
IbrancePalbociclib13$195,360
XtandiEnzalutamide13$191,912
BrukinsaZanubrutinib15$133,390
TasignaNilotinib Hcl13$131,331
XareltoRivaroxaban15$15,142
EliquisApixaban14$12,355
Anastrozole227$4,520
Prochlorperazine Maleate123$3,707
Ondansetron Hcl76$2,558
Dexamethasone113$1,257
Triamcinolone Acetonide24$1,164
Imatinib Mesylate13$1,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$26,550$694,49731 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$165$407,18324 claims
Incyte CorporationJakafi$205$211,19712 claims
PfizerIbrance, Eliquis$37,317$207,71527 claims
Astellas Pharma US IncXtandi$71$191,91213 claims
Beigene USA, Inc.Brukinsa$97$133,39015 claims
NovartisTasigna$440$131,33113 claims
Johnson & JohnsonXarelto$417$15,14215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →